Home › NDC Lookup › Ingredients › Nystatin › 00832-0465-15
Nyamyc Nystatin 100000 [USP'U]/g Powder — NDC 00832-0465-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Nyamyc Nystatin 100000 [USP'U]/g Powder — NDC 0832-0465-15 (Billing 00832-0465-15)

by Upsher-Smith Laboratories, LLC · 1 BOTTLE, PLASTIC in 1 CARTON / 15 g in 1 BOTTLE, PLASTIC

This is a package of Nyamyc Nystatin 100000 [USP'U]/g Powder from Upsher-Smith Laboratories, LLC, marketed since May 2005 and currently FDA-listed; retail pharmacies pay about $0.4214 per g (NADAC).

NDC 00832-0465-15
🏷️ FDA NDC (as labeled) 0832-0465-15 billing pads the labeler segment with a zero
This package
Contains15 g in 1 bottle, plastic Cost per g$0.4214 NADAC Per package$6.32 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.7454/unit · Part D plans $0.3442/unit — full pricing hub ↓
Product page 00832-0465-60 Also comes in: 30 g 0832-0465-30 60 g 0832-0465-60
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0832-0465-15 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0832 labeler · 0465 product · 15 package
Package marketed since
May 3, 2005
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0308320465159
Medicaid fills, this package
9,931 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Nystatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 23, 2026 — Subpotent Drug: Low out of specification assay results performed during long-term stability testing. (Padagis US LLC) · FDA recall D-0677-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0832-0465-15
Product NDC 0832-0465
11-digit billing NDC 00832046515
NCPDP billing unit GM — per gram (weight)
RxCUI 584414, 646456
UNII BDF1O1C72E
UPC 0308320465159
Application # ANDA065183
SPL Set ID 01b44f91-9b68-464a-9693-b5d3e793bf3c
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2005-05-03
Route TOPICAL
Dosage form POWDER
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080002920
GPI class Nyamyc
GCN Seq No 007284
GCN 30160
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYAMYC 100,000 UNIT/GM POWDER
FDB brand name Nyamyc
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007284
  • GCN: 30160
  • GPI-14 (Medi-Span): 90150080002920
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 584414
Why two NDCs? The FDA registers this code as 0832-0465-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00832-0465-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYAMYC 100,000 UNIT/GM POWDER Ingredient Nystatin
📖 What it is MedlinePlus · NLM

Topical nystatin is used to treat fungal infections of the skin. Nystatin is in a class of antifungal medications called polyenes. It works by stopping the growth of fungi that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.421 $6.32 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.7454 $11.18 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3442 $5.16 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.473 $0.306
▲ Up 17% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00832-0465-15 You're viewing this 1 BOTTLE, PLASTIC in 1 CARTON / 15 g in 1 BOTTLE, PLASTIC $0.4214 / g $6.32 2005-05-03 — Active
00832-0465-30 0832-0465-30 1 BOTTLE, PLASTIC in 1 CARTON / 30 g in 1 BOTTLE, PLASTIC $0.3134 / g $9.40 2005-05-03 — Active
00832-0465-60 0832-0465-60 Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 60 g in 1 BOTTLE, PLASTIC $0.2574 / g $15.44 2012-03-09 — Active

Per g, this pack runs about 64% above the cheapest pack (NDC 00832-0465-60, $0.2574 vs $0.4214 NADAC).

This pack accounts for about 30% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 bottle, plastic in 1 carton / 15 g in 1 bottle, plastic.
What NDC number is used to bill for this package of Nyamyc Nystatin 100000 [USP'U]/g Powder?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystop 100000 [USP'U]/g 00574-2008-02 Padagis 60 g $0.257 AT Availability likely save 39%
Nystatin Topical Powder 100000 U/g 42806-0178-15 Epic 15 g $0.307 AT FDA listed save 27%
Nystatin 100000 [USP'U]/g 75907-0060-30 Dr. 30 g $0.313 AT Availability likely save 26%
Nyamyc 100000 [USP'U]/gthis 00832-0465-15 Upsher-Smith 1 bottle $0.421 AT Availability likely —
Klayesta 100000 U/g 42806-0186-15 Epic 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/g 68382-0370-01 Zydus 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/g 69315-0306-15 Leading 15 g $0.421 AT Availability likely —
Nystatin 100000 [USP'U]/g 72603-0491-01 Northstar 15 g $0.421 AT Availability likely —
Nystatin Topical Powder 100000 U/g 42806-0185-15 Epic 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8696-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8697-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 63629-8698-01 Bryant 60 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 70771-1585-01 Zydus 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2845-01 Bryant 15 g — AT FDA listed —
Nystop 100000 [USP'U]/g 71335-2869-01 Bryant 30 g — AT FDA listed —
Nystop 100000 [USP'U]/g 72162-1124-02 Bryant 15 g — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2005
On the market since
May 2005
📍
2026
Currently FDA-listed
21 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Nystatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerUpsher-Smith Laboratories, LLC
Application holderUPSHER SMITH LABORATORIES LLC
FDA applicationANDA065183 (ANDA)
Labeler code00832
First marketedMay 2005
Product typeHuman Prescription Drug
Portfolio229 products on file

More NDCs from Upsher-Smith Laboratories, LLC labeler code 00832

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 43 words ▾

INDICATIONS AND USAGE Nyamyc® (Nystatin Topical Powder, USP) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nyamyc® (Nystatin Topical Powder, USP) is not indicated for systemic, oral, intravaginal or ophthalmic use.

⏱️ Dosage and Administration 59 words ▾

DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.

⛔ Contraindications 20 words ▾

CONTRAINDICATIONS Nyamyc® (Nystatin Topical Powder, USP) is contraindicated in patients with a history of hypersensitivity to any of its components.

🤒 Adverse Reactions 40 words ▾

ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. [see PRECAUTIONS: General ].

🤰 Pregnancy 65 words ▾

Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

🧒 Pediatric Use 22 words ▾

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. [see DOSAGE AND ADMINISTRATION ].

🧓 Geriatric Use 55 words ▾

Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🧬 Clinical Pharmacology 155 words ▾

CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.

On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.

This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

📦 How Supplied / Storage and Handling 84 words ▾

HOW SUPPLIED Nyamyc® (Nystatin Topical Powder, USP) 100,000 units nystatin per gram is available as follow: Bottles of 15 g (NDC 0832-0465-15) Bottles of 30 g (NDC 0832-0465-30) Bottles of 60 g (NDC 0832-0465-60) STORAGE Nyamyc® (Nystatin Topical Powder, USP) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat (40°C/104°F). Keep tightly closed.

Keep out of reach of children. Nyamyc is a registered trademark of Upsher-Smith Laboratories, LLC.

📦 Storage and Handling 50 words ▾

STORAGE Nyamyc® (Nystatin Topical Powder, USP) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat (40°C/104°F). Keep tightly closed. Keep out of reach of children. Nyamyc is a registered trademark of Upsher-Smith Laboratories, LLC.

📋 Description 37 words ▾

DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. Nyamyc® (Nystatin Topical Powder, USP) is for dermatologic use. Nyamyc® (Nystatin Topical Powder, USP) contains 100,000 USP nystatin units per gram dispersed in talc. Chemical Structure

💬 Information for Patients 93 words ▾

INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Nyamyc® (Nystatin Topical Powder, USP) should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin.

No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.

Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. [see DOSAGE AND ADMINISTRATION ]. Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

🍼 Nursing Mothers 25 words ▾

Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

🧬 Pharmacokinetics 11 words ▾

Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

📄 Package Label / Principal Display Panel 37 words ▾

PRINCIPAL DISPLAY PANEL - 15 gram Bottle Carton NDC 0832-0465-15 Nyamyc ® Nystatin Topical Powder, USP 100,000 USP units per gram FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT. 15 grams Rx only UPSHER-SMITH label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
9.9K
Units reimbursed last 4 qtrs
204.2K
Gross reimbursed last 4 qtrs
$152.2K
Avg / prescription
$15.33
Avg / unit
$0.7453
Latest quarter Q1 2026
841Rx
Medicaid pays / g
$0.7453
gross reimbursed
vs
NADAC / g
$0.4214
acquisition cost
=
Spread
+$0.3239
+77% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 3,569 Rx Managed care · 6,362 Rx
State Medicaid map
Alaska: no data reported AK Maine: 1,245 units · 89.2 per 100k residents ME Washington: 3,375 units · 43.2 per 100k residents WA Idaho: no data reported ID Montana: 555 units · 49.0 per 100k residents MT North Dakota: no data reported ND Minnesota: 4,052 units · 70.6 per 100k residents MN Wisconsin: 2,960 units · 50.1 per 100k residents WI Michigan: 8,010 units · 79.8 per 100k residents MI New York: 25,710 units · 131 per 100k residents NY Vermont: no data reported VT New Hampshire: 1,185 units · 84.5 per 100k residents NH Oregon: 1,935 units · 45.7 per 100k residents OR Nevada: 345 units · 10.8 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 4,650 units · 145 per 100k residents IA Illinois: 5,685 units · 45.3 per 100k residents IL Indiana: 4,891 units · 71.3 per 100k residents IN Ohio: 18,091 units · 154 per 100k residents OH Pennsylvania: 19,875 units · 153 per 100k residents PA New Jersey: 29,583 units · 318 per 100k residents NJ Massachusetts: 2,807 units · 40.1 per 100k residents MA California: 18,317 units · 47.0 per 100k residents CA Utah: 2,895 units · 84.7 per 100k residents UT Colorado: 1,758 units · 29.9 per 100k residents CO Nebraska: 1,920 units · 97.1 per 100k residents NE Missouri: 4,260 units · 68.8 per 100k residents MO Kentucky: 5,563 units · 123 per 100k residents KY West Virginia: 2,985 units · 169 per 100k residents WV Virginia: 3,220 units · 36.9 per 100k residents VA Maryland: 5,070 units · 82.0 per 100k residents MD Connecticut: 3,990 units · 110 per 100k residents CT Rhode Island: 435 units · 39.7 per 100k residents RI Arizona: 1,890 units · 25.4 per 100k residents AZ New Mexico: no data reported NM Kansas: 1,740 units · 59.2 per 100k residents KS Arkansas: no data reported AR Tennessee: 375 units · 5.3 per 100k residents TN North Carolina: 5,115 units · 47.2 per 100k residents NC South Carolina: no data reported SC Delaware: 840 units · 81.5 per 100k residents DE Oklahoma: 315 units · 7.8 per 100k residents OK Louisiana: 765 units · 16.7 per 100k residents LA Mississippi: 270 units · 9.2 per 100k residents MS Alabama: 300 units · 5.9 per 100k residents AL Georgia: 1,440 units · 13.1 per 100k residents GA D.C.: 399 units · 58.8 per 100k residents DC Hawaii: no data reported HI Texas: 5,105 units · 16.7 per 100k residents TX Florida: 300 units · 1.3 per 100k residents FL
Units reimbursed · per 100k residents
1.3318
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 318 /100k
2 West Virginia 169 /100k
3 Ohio 154 /100k
4 Pennsylvania 153 /100k
5 Iowa 145 /100k
6 New York 131 /100k
7 Kentucky 123 /100k
8 Connecticut 110 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle00832-0465-60 16,415 Rx · $408,188
1 bottle this page00832-0465-15 9,931 Rx · $152,216
1 bottle00832-0465-30 6,459 Rx · $124,046
Drug total (last 4 qtrs): 32,805 Rx · 1,465,530 units · $684,450 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nyamyc — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nyamyc. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$227.2K
Claims incl. refills
9.4K
Beneficiaries
6.8K
Spend / beneficiary
$33.63
Spend / claim
$24.30
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Nyamyc (this brand).

Top reported reactions

Nausea1,990
Fatigue1,779
Diarrhoea1,774
Pneumonia1,639
Dyspnoea1,486
Vomiting1,373
Pain1,225

Age at onset

Neonate25
Infant58
Child157
Adolescent116
Adult2,258
Elderly1,784

Reporter sex

26,206 reports
Male · 38%
Female · 62%
Unknown · 0%

Serious outcomes

Hospitalization11,786
Death3,625
Life-threatening1,739
Disabling716
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 2,329 819
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00832-0357-11 · Upsher-Smith 00832-0510-00 · Upsher-Smith →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.